Anthem Bioscienc

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0CZ201020
  • NSEID: ANTHEM
  • BSEID: 544449
INR
765.35
-11.75 (-1.51%)
BSENSE

May 25

BSE+NSE Vol: 4.23 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Glenmark Pharma
Biocon
Anthem Bioscienc
Ipca Labs
Laurus Labs
Ajanta Pharma
Gland Pharma
J B Chemicals &
Alkem Lab
Abbott India
Glaxosmi. Pharma

Why is Anthem Biosciences Ltd ?

1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 19.93%
  • Healthy long term growth as Operating profit has grown by an annual rate 44.32%
  • The company is Net-Debt Free
2
The company declared positive results in Mar'26 after negative results in Dec'25
  • NET SALES(Q) Highest at Rs 610.94 cr
  • PBDIT(Q) Highest at Rs 267.21 cr.
  • OPERATING PROFIT TO NET SALES(Q) Highest at 43.74%
3
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 3.87% over the previous quarter and collectively hold 12.83% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Anthem Bioscienc should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
29.80%
EBIT Growth (5y)
44.32%
EBIT to Interest (avg)
76.10
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.63
Tax Ratio
25.75%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.83%
ROCE (avg)
32.62%
ROE (avg)
19.93%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
72
Industry P/E
0
Price to Book Value
13.68
EV to EBIT
56.81
EV to EBITDA
50.16
EV to Capital Employed
18.54
EV to Sales
20.43
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
32.64%
ROE (Latest)
21.62%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bollinger Bands
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company
NET SALES(Q)

Highest at Rs 610.94 cr

PBDIT(Q)

Highest at Rs 267.21 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 43.74%

PBT LESS OI(Q)

Highest at Rs 225.73 cr.

PAT(Q)

Highest at Rs 189.09 cr.

EPS(Q)

Highest at Rs 3.38

0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Anthem Bioscienc

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 225.73 cr has Grown at 43.0% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 157.84 Cr
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 189.09 cr has Grown at 50.5% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 125.68 Cr
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 610.94 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Net Sales - Quarterly
At Rs 610.94 cr has Grown at 22.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 499.15 Cr
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 267.21 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 43.74%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 225.73 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 189.09 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 3.38
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Anthem Bioscienc

Non Operating Income - Quarterly
Highest at Rs 51.21 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income